{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:01:33Z","timestamp":1790085693515,"version":"4.0.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>This case series describes adults with aquaporin 4 immunoglobulin G\u2013seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) who switched treatment from eculizumab to satralizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Case information for patients with AQP4-IgG+ NMOSD who received satralizumab for \u22656 months was obtained from US healthcare providers from April 2022 to January 2024. Patient characteristics, examination findings, diagnostic test results, treatment response, and adverse events were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 5 patients (4 women and 1 man) included, ages ranged from 32 to 81 years and 4 patients self-identified as Black\/African American and 1 as White. Time since confirmed NMOSD diagnosis ranged from 1 to 14 years. The reasons for initiating satralizumab were route of administration\/patient preference (n=3) and inadequate disease control with eculizumab (n=2). The duration of satralizumab treatment was 10 to 31 months. All 5 patients were relapse-free with satralizumab, and adverse events they experienced were primarily asymptomatic laboratory abnormalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In this retrospective case series, satralizumab was effective and well tolerated in patients with NMOSD who switched from eculizumab due to route of administration\/patient preference or inadequate disease control. These outcomes align with the long-term efficacy and safety outcomes with satralizumab in the phase 3 SAkura clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1526563","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T05:10:43Z","timestamp":1736485843000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G\u2013seropositive neuromyelitis optica spectrum disorder: a case series report"],"prefix":"10.3389","volume":"15","author":[{"given":"Hesham","family":"Abboud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Subei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buse","family":"Sengul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Goulette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"Walch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanie","family":"Cot\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Z.","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ferayorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shervin","family":"Gholizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N Engl J Med"},{"key":"B2","unstructured":"Alexion Pharmaceuticals\n          Prescribing information\n          \n          2024"},{"key":"B3","unstructured":"Alexion Pharmaceuticals\n          Prescribing information\n          \n          2024"},{"key":"B4","unstructured":"Horizon Therapeutics\n          Prescribing information\n          \n          2021"},{"key":"B5","unstructured":"Genentech, Inc\n          Prescribing information\n          \n          2022"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200071","article-title":"Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar","volume":"10","author":"Kleiter","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","first-page":"104025","DOI":"10.1016\/j.msard.2022.104025","article-title":"Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar","volume":"66","author":"Yamamura","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06495-w","article-title":"A safe change from eculizumab to satralizumab in a patient with neuromyelitis optica spectrum disorder","volume":"44","author":"Funakoshi","year":"2023","journal-title":"Neurol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"105041","DOI":"10.1016\/j.msard.2023.105041","article-title":"Treatment transitions in neuromyelitis optica spectrum disorder increase risk for disease advancement","volume":"79","author":"Okuda","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11529-6","article-title":"Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort","volume":"270","author":"Gholizadeh","year":"2023","journal-title":"J Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200124","article-title":"International Delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"104949","DOI":"10.1016\/j.msard.2023.104949","article-title":"Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment","volume":"79","author":"Sen","year":"2023","journal-title":"Mult Scler Relat Disord"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1526563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T05:10:48Z","timestamp":1736485848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1526563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2024.1526563"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1526563","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"article-number":"1526563"}}